Development of Novel MRI Contrast Agents
Tissue, Kirsten and Biros, Shannon, "Development of Novel MRI Contrast Agents" (2011). Student Summer Scholars. 72.
This document is currently not available here.
Medical resonance imaging (MRI) is sometimes performed using ionized gadolinium (Gd3+) as a contrast agent. As gadolinium is a nephrotoxin, it is important to use a chelating agent to prevent toxicity to the patient. Current chelating agents are available; however, they suffer from a lack of water solubility or by having a negative affect on water’s relaxivity rates. An ideal chelating agent binds well to Gd3+ while allowing it to simultaneously interact with individual water molecules. Our lab is developing a novel class of chelating agents containing carbamoylmethyl phosphine oxides (CMPO’s), which have the potential to be more soluble in water than current commercially available agents while retaining a favorable affect on water relaxivity.